On-line Courses
-
CME: Leukemia
CME Credit: 1.00 AMA -
CME: Pancreatic Cancer
CME Credit: None -
CME: Leukemia
CME Credit: None -
CME: Bladder Cancer
CME Credit: None -
CME: Leukemia
CME Credit: 1.00 AMA ANCC -
CME: Lymphoma
CME Credit: None -
CME: Sarcoma
CME Credit: None -
CME: Melanoma
CME Credit: None -
CME: Prostate Cancer
CME Credit: None
Events
News and Perspectives
COVID-19: ASCO Patient Care Link
American Society of Clinical Oncology (ASCO) Patient Care Recommendations
Read more...COVID-19: NCCN Recommendations
National Comprehensive Cancer Network (NCCN) Recommendations
Read more...COVID-19: ASCO Provider and Practice Link
American Society of Clinical Oncology (ASCO) Provider and Practice Recommendations
Read more...Prostate Cancer: More positive data from TITAN trial
A double-blind, phase 3 TITAN trial, which randomly assigned patients with metastatic castration-sensitive prostate cancer to receive apalutamide or placebo, in addition to continuous androgen deprivation therapy (ADT), previously demonstrated significant improvement in radiographic progression-free survival (PFS) and overall survival in patients who received apalutamide (Chi KN, et al. N Engl J Med. 2019;381:13-24). At the 2020 Genitourinary Cancers Symposium, post hoc analysis data were presented which showed that addition of apalutamide to ADT also prolonged PFS2 (defined as the time from randomization to disease progression on 1st subsequent prostate cancer therapy or death, whichever occurred first) regardless of the type (hormonal or taxane) of the 1st subsequent life-prolonging therapy.
Read more...Multiple Myeloma: Positive ICARIA-MM Data Lead to Isatuximab FDA Approval
On March 2, 2020, FDA approved an anti-CD38 monoclonal antibody isatuximab in combination with pomalidomide and low-dose dexamethasone (Isa-Pd) for patients with relapsed and refractory multiple myeloma (RRMM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. This approval was based on the positive progression-free survival (PFS) data from a randomized, open-label, two-arm, phase 3 trial, ICARIA-MM; at a median follow-up of 11.6 months, median PFS was 11.5 months in the Isa-Pd arm versus 6.5 months in the Pd arm. Isatuximab represents an important new treatment option for patients with RRMM, especially those who are refractory to lenalidomide and a proteasome inhibitor.
Read more...Myeloma: Update from Orlando
Dr. Joseph Mikhael of the Translational Genomics Research Institute in Phoenix, Arizona, shares his perspective on new multiple myeloma data.
Myeloma: Update from Orlando
Dr. Ola Landgren of Memorial Sloan Kettering Cancer Center in New York City, shares his perspective on new multiple myeloma data."
PNCA: The Impact of Translational Science on Cancer
Dr. Linda Malkas of City of Hope presents the Grand Rounds lecture at Eisenhower Health where she talks about her journey toward identifying proliferating cell nuclear antigen (PCNA) as a potentially major player in cancer, and an early development of a small molecule inhibitor of a cancer-associated form of PCNA. She also discusses potential advantages of targeting molecular hubs, as opposed to targeting enzymatic activities, of cancer cells.
Myeloma: Update from Orlando
Dr. Shaji Kumar of Mayo Clinic in Rochester, Minnesota, shares his perspective on new multiple myeloma data.
Prostate Cancer: Update from Chicago
Neal D. Shore, MD, reviews exciting new prostate cancer data.
Bladder Cancer: Update from Chicago
Guru P. Sonpavde, MD, shares exciting new bladder cancer data.
Lymphocytic Leukemia: Update from Chicago
Kanti R. Rai, MD, shares exciting new chronic lymphocytic leukemia data.
Multiple Myeloma: Update from Chicago
Joseph Mikhael, MD, gives his perspective on new daratumumab data.
Advance or Metastatic Urothelial Cancer: Update from Chicago
Daniel P. Petrylak, MD, gives an update on enfortumab vedotin EV-201 trial